

Kristina M Brooks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231040/publications.pdf>

Version: 2024-02-01

33
papers

1,106
citations

643344

15
h-index

466096

32
g-index

33
all docs

33
docs citations

33
times ranked

2292
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , . | 1.3 | 0 |
| 2 | Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 343-350. | 0.9 | 3 |
| 3 | The use of technology-based adherence monitoring in the treatment of hepatitis C virus. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956. | 1.1 | 2 |
| 4 | Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 36-48. | 2.3 | 29 |
| 5 | Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428. | 0.5 | 12 |
| 6 | Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021, 35, 2481-2487. | 1.0 | 8 |
| 7 | Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa564. | 0.4 | 14 |
| 8 | Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. <i>Aids</i> , 2021, 35, 407-417. | 1.0 | 15 |
| 9 | Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3303-3310. | 1.3 | 9 |
| 10 | Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 323-330. | 0.9 | 26 |
| 11 | Tenofovir alafenamide use in pregnant and lactating women living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 333-342. | 1.5 | 28 |
| 12 | Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 173-180. | 0.9 | 6 |
| 13 | Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2360-2364. | 1.3 | 13 |
| 14 | Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2352-2359. | 1.3 | 9 |
| 15 | Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?. <i>Pharmacotherapy</i> , 2019, 39, 576-598. | 1.2 | 41 |
| 16 | Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifampentine. <i>Clinical Infectious Diseases</i> , 2018, 67, 193-201. | 2.9 | 49 |
| 17 | Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 332-339. | 1.0 | 5 |
| 18 | The role of jab1, a putative downstream effector of the neurotrophic cytokine macrophage migration inhibitory factor (MIF) in zebrafish inner ear hair cell development. <i>Experimental Neurology</i> , 2018, 301, 100-109. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza A M1/M2 translation. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 25-34. | 1.1 | 17 |
| 20 | Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 364-373. | 2.3 | 93 |
| 21 | JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. <i>Journal of Clinical Investigation</i> , 2018, 128, 3041-3052. | 3.9 | 387 |
| 22 | Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1056-1059. | 2.3 | 29 |
| 23 | Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837. | 0.5 | 12 |
| 24 | Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy Tube Administration. <i>Pharmacotherapy</i> , 2017, 37, e82-e89. | 1.2 | 12 |
| 25 | Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, . | 1.4 | 42 |
| 26 | Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 59-79. | 1.3 | 15 |
| 27 | Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx202. | 0.4 | 56 |
| 28 | Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery. <i>Journal of the Endocrine Society</i> , 2017, 1, 994-1001. | 0.1 | 9 |
| 29 | Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers. <i>Circulation</i> , 2016, 134, 1909-1911. | 1.6 | 18 |
| 30 | National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain. <i>Journal of the American College of Radiology</i> , 2016, 13, 237-241. | 0.9 | 96 |
| 31 | Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 565-573. | 1.1 | 20 |
| 32 | A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs. <i>Pharmaceutical Research</i> , 2016, 33, 72-82. | 1.7 | 4 |
| 33 | Pharmacotherapy Challenges of Fontan-Associated Plastic Bronchitis: A Rare Pediatric Disease. <i>Pharmacotherapy</i> , 2013, 33, 922-934. | 1.2 | 21 |